
|Articles|February 1, 2005
Ocular bioavailability of glaucoma drug improves with new formulation
Timolol maleate ophthalmic solution 0.5% (Istalol, ISTA Pharmaceuticals), available in a new, once-a-day formulation, is as effective as a standard 0.5% timolol maleate ophthalmic solution administered twice daily to treat elevated IOP in ocular hypertension and open-angle glaucoma.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
Glaucoma innovation: Eight themes to watch in 2026
3
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5












































